SYNOPSIS: This chemical major completes a $150 million acquisition of US-based Jayhawk Fine Chemicals, funded through equity and debt. The company expects full consolidation and EPS accretion, strengthening its global specialty chemicals platform.
During Monday’s trading session, shares of one of the leading providers of custom synthesis and specialty chemicals are in focus on the stock exchanges, after it strengthened its global presence by completing a $150 million (~Rs. 1,369 crore) acquisition of a US-based specialty chemicals firm.
With a market cap of Rs. 14,004 crores, shares of Anupam Rasayan India Limited were trading at Rs. 1,230 on BSE, as against its previous closing price of Rs. 1,237.8. The stock has delivered positive returns of around 73 percent in one year, and has gained by over 10 percent in the last six months.
What’s the News:
As per its latest regulatory disclosures, Anupam Rasayan India Limited has completed the acquisition of a 100 percent equity stake in Jayhawk Fine Chemicals Corporation, a US-based specialty chemical company and part of the CABB Group. The transaction, valued at ~$150 million (nearly Rs. 1,369.2 crores), was executed through its wholly owned subsidiary, Doriath S.à r.l.
The total consideration for the acquisition has been structured through a mix of equity and debt. Around $109 million has been raised through the issuance of Class B non-voting shares by Doriath S.à r.l., while the remaining $41 million has been funded through debt.
In terms of funding sources, $129 million has been backed by Altis XII Pte. Ltd., an affiliate of funds managed by Oaktree Capital Management, a global alternative investment manager. The balance of $21 million has been financed by Axis Bank.
Following the completion of the transaction, Jayhawk will be fully consolidated into Anupam Rasayan, and the company expects the acquisition to be earnings per share (EPS) accretive.
With the addition of Jayhawk, the company advances further along the value chain, moving closer to end-use applications by manufacturing critical N-1 molecules for high-growth sectors such as electronics, semiconductors, aviation, and performance materials.
About the Target Entity
Founded in 1941 and headquartered in Kansas, USA, Jayhawk is part of the CABB Group and is engaged in the business of custom manufacturing of advanced intermediates, active ingredients, and high-performance materials. It operates a manufacturing site equipped with advanced multipurpose plants, pilot facilities, and modern analytical R&D labs capable of executing complex chemistries, including halogenation, oxidation, nitration, and phosphorus chemistry.
With 8+ decades of operating history, Jayhawk has developed strong relationships with global customers and earned a reputation for reliable, high-quality, and technically advanced manufacturing. Nearly 65 percent of its revenue comes from performance materials, catering to industries such as electronics, energy and infrastructure, aerospace, and polymers, with a significant share derived from the US market.
Financials & More:
Anupam Rasayan reported a significant growth in revenue from operations, experiencing a year-on-year increase of over 31 percent, from Rs. 390 crores in Q3 FY25 to Rs. 512 crores in Q3 FY26. Likewise, its net profit jumped during the same period from Rs. 54 crores to Rs. 61 crores, representing a rise of around 13 percent YoY.
Anupam Rasayan India Limited is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. It has two verticals: Life science-related Specialty Chemicals comprising products related to agrochemicals, personal care and pharmaceuticals, Other Specialty Chemicals comprising specialty pigment and dyes and polymer additives. It has around 30,000 MT+ manufacturing capacity, spread over 6 manufacturing facilities.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Anupam Rasayan: Chemical Stock Acquires US-Based Company for ₹1,369 Cr appeared first on Trade Brains.